Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grifols, S.A. stock logo
GRFS
Grifols
$8.73
+0.5%
$7.75
$6.96
▼
$9.77
$5.94B0.75650,539 shs441,040 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.28
-2.6%
$32.52
$21.86
▼
$45.42
$6.89B0.951.51 million shs1.05 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grifols, S.A. stock logo
GRFS
Grifols
0.00%+3.08%+13.74%+11.84%-0.23%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%+11.96%+27.87%-21.80%+43.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grifols, S.A. stock logo
GRFS
Grifols
$8.73
+0.5%
$7.75
$6.96
▼
$9.77
$5.94B0.75650,539 shs441,040 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.28
-2.6%
$32.52
$21.86
▼
$45.42
$6.89B0.951.51 million shs1.05 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grifols, S.A. stock logo
GRFS
Grifols
0.00%+3.08%+13.74%+11.84%-0.23%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%+11.96%+27.87%-21.80%+43.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grifols, S.A. stock logo
GRFS
Grifols
1.67
Reduce$9.003.09% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.62
Moderate Buy$44.6034.01% Upside

Current Analyst Ratings Breakdown

Latest GRFS and IMVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetHold$30.00 ➝ $33.00
11/10/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetOverweight$45.00 ➝ $47.00
11/4/2026
Grifols, S.A. stock logo
GRFS
Grifols
UpgradeSell (D+) ➝ Hold (C-)
11/3/2026
Grifols, S.A. stock logo
GRFS
Grifols
DowngradeHold ➝ Strong Sell
10/26/2026
Grifols, S.A. stock logo
GRFS
Grifols
Lower Price TargetNeutral$10.00 ➝ $9.00
10/2/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Reiterated RatingSell (D-)
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Reiterated RatingBuy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Reiterated RatingPositive
9/23/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Reiterated RatingBuy
8/25/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Reiterated RatingOverweight
8/17/2026
Grifols, S.A. stock logo
GRFS
Grifols
UpgradeSell (D) ➝ Sell (D+)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grifols, S.A. stock logo
GRFS
Grifols
$7.60B0.78$1.42 per share6.14$12.64 per share0.69
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grifols, S.A. stock logo
GRFS
Grifols
$454.82MN/AN/A6.980.275.54%6.21%2.39%N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.56N/AN/AN/AN/A-63.01%-56.19%N/A

Latest GRFS and IMVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q2 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.7370-$0.47+$0.2670-$0.4060N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Grifols, S.A. stock logo
GRFS
Grifols
$0.273.09%N/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A

Latest GRFS and IMVT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/3/2026
Grifols, S.A. stock logo
GRFS
Grifols
$0.16863.85%12/3/202612/3/20261/11/2027
11/5/2026
Grifols, S.A. stock logo
GRFS
Grifols
$0.16864%12/3/202612/3/202612/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grifols, S.A. stock logo
GRFS
Grifols
1.05
2.33
0.82
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.31
7.31

Institutional Ownership

CompanyInstitutional Ownership
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%

Insider Ownership

CompanyInsider Ownership
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Grifols, S.A. stock logo
GRFS
Grifols
25,247680.58 million679.28 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
315206.95 million203.02 millionOptionable

Recent News About These Companies

Immunovant (NASDAQ:IMVT) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen Upgrades Immunovant (NASDAQ:IMVT) to Hold
Immunovant (IMVT) Q2 2027 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
What Immunovant (IMVT) Said on Its Q2 Earnings Call
Immunovant (IMVT) Expected to Post Earnings on Monday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Grifols stock logo

Grifols NASDAQ:GRFS

$8.73 +0.04 (+0.46%)
Closing price 04:00 PM Eastern
Extended Trading
$8.60 -0.13 (-1.43%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$33.28 -0.90 (-2.63%)
Closing price 04:00 PM Eastern
Extended Trading
$33.30 +0.02 (+0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.